Improvement of in vitro stability and pharmacokinetics of hIFN-α by fusing the carboxyl-terminal peptide of hCG β-subunit

Journal of Biotechnology
N CeaglioM Oggero

Abstract

Improving in vivo half-life and in vitro stability of protein-based therapeutics is a current challenge for the biopharmaceutical industry. In particular, recombinant human interferon alpha-2b (rhIFN-α2b), which belongs to a group of cytokines extensively used for the treatment of viral diseases and cancers, shows a poor stability in solution and an extremely short plasma half-life which determines a strict therapeutic regimen comprising high and repeated doses. In this work, we have used a strategy based on the fusion of the carboxyl-terminal peptide (CTP) of human chorionic gonadotropin (hCG) β-subunit, bearing four O-linked oligosaccharide recognition sites, to each or both N- and C-terminal ends of rhIFN-α2b. Molecules containing from 5 (CTP-IFN and IFN-CTP) to 9 (CTP-IFN-CTP) O-glycosylation sites were efficiently expressed and secreted to CHO cells supernatants, and exhibited antiviral and antiproliferative bioactivities in vitro. Significant improvements in pharmacokinetics in rats were achieved through this approach, since the doubly CTP-modified IFN variant showed a 10-fold longer elimination half-life and a 19-fold decreased plasma apparent clearance compared to the wild-type cytokine. Moreover, CTP-IFN-CTP demonstrat...Continue Reading

References

May 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·F A FaresI Boime
Jan 1, 1990·Biologicals : Journal of the International Association of Biological Standardization·T NedermanL Sjödin
Mar 1, 1985·Proceedings of the Society for Experimental Biology and Medicine·P O'KellyT Cesario
Jan 1, 1981·Annual Review of Biochemistry·J G Pierce, T F Parsons
Jan 1, 1997·Critical Reviews in Biochemistry and Molecular Biology·P M Rudd, R A Dwek
Jul 23, 1998·Critical Reviews in Biochemistry and Molecular Biology·P Van den SteenG Opdenakker
Aug 26, 1999·International Journal of Pharmaceutics·W Wang
Dec 12, 2001·Protein Engineering·Y MarkertR Ulbrich-Hofmann
Jun 8, 2002·Advanced Drug Delivery Reviews·M J RobertsJ M Harris
Jan 15, 2003·Human Reproduction·J KleinJ W Lustbader
Mar 4, 2003·Nature Biotechnology·Steve ElliottJoan Egrie
Mar 14, 2003·Drug Discovery Today·Shannon A MarshallJohn R Desjarlais
Aug 23, 2003·Seminars in Liver Disease·Simon C J Pedder
Sep 12, 1957·Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character·A ISAACS, J LINDENMANN
Feb 27, 2004·Biochemical and Biophysical Research Communications·Byung-Moon KimYounghoon Lee
Sep 17, 2004·Journal of Medicinal Chemistry·Tal Peleg-ShulmanYoram Shechter
Apr 15, 2005·Clinical Pharmacokinetics·Iftekhar Mahmood, Martin D Green
Jun 17, 2005·Journal of Pharmaceutical Sciences·Angus M Sinclair, Steve Elliott
Nov 30, 2005·Biochemical and Biophysical Research Communications·Dong Eok LeeOok Joon Yoo
Dec 13, 2005·Pharmacy World & Science : PWS·Stefan SleijferGerrit Stoter
Jan 21, 2006·International Journal of Pharmaceutics·Seung Ho Choi, Tae Gwan Park
Jun 14, 2006·Biochimica Et Biophysica Acta·Suzan WopereisRon A Wevers
Nov 4, 2006·Molecular and Cellular Endocrinology·Laurence A Cole, Sarah A Khanlian
May 16, 2007·The Journal of Biological Chemistry·Nicole A de WeerdPaul J Hertzog
Dec 1, 2007·Nature Reviews. Drug Discovery·Ernest C BordenGeorge R Stark
Dec 22, 2007·Nature Reviews. Drug Discovery·Benjamin LeaderDavid E Golan
May 2, 2008·Journal of Controlled Release : Official Journal of the Controlled Release Society·Liyun YuanWei-Chiang Shen
Feb 10, 2009·Journal of Pharmaceutical Sciences·Kaya BorkWenke Weidemann
Nov 6, 2009·Current Opinion in Biotechnology·Yves Durocher, Michael Butler
Nov 19, 2009·The FEBS Journal·Pia H JensenNicolle H Packer
Jan 14, 2010·Journal of Biotechnology·Natalia CeaglioMarcos Oggero
Jul 14, 2010·Placenta·L A Cole
Oct 1, 2011·Nature Methods·Thomas Nordahl PetersenHenrik Nielsen

❮ Previous
Next ❯

Citations

Mar 30, 2019·Journal of Peptide Science : an Official Publication of the European Peptide Society·Claudia BelloAnna Maria Papini
Jul 26, 2018·Cancer Gene Therapy·Zinaida A DubeykovskayaTimothy C Wang
Jan 3, 2021·Journal of Biotechnology·María de Los Milagros SalesNatalia Ceaglio

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.